September 9, 2021 – Roche (Basel, Switzerland) announced it has signed a definitive share purchase agreement to acquire 100% of the outstanding shares of the TIB Molbiol Group.
Roche says the acquisition of the TIB Molbiol Group will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as the identification of SARS-CoV-2 variants.
TIB Molbiol’s comprehensive portfolio of over 45 CE-IVD assays and more than 100 research-use assays are already available on Roche’s large installed base of LightCycler PCR systems and MagNA Pure sample preparation systems.
“With this acquisition, we can expand our offering of tests of existing pathogens and our response to emerging pathogens and potential health threats,” said Thomas Schinecker, CEO Roche Diagnostics. “At the onset of the COVID-19 pandemic, our collaboration provided the first research-use-only SARS-CoV-2 detection test that was provided in January 2020, only days after the new coronavirus was first sequenced. Together, we can further improve patient outcomes with innovative diagnostic solutions that alleviate healthcare costs.”
The transaction is expected to close in the fourth quarter of 2021, subject to customary closing conditions.